Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24


19391 items
5:59 PM, Aug 03, 2018  |  BioCentury | Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
5:46 PM, Aug 03, 2018  |  BioCentury | Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
4:41 PM, Aug 03, 2018  |  BioCentury | Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
2:35 PM, Aug 03, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc. CompanyDatePre/post mkt2Q18 EPS est2Q17 EPSExpected chgBausch Health Companies Inc. (TSX:BHC; NYSE:BHC) (A)8/7Pre$0.80$1.03-22%Jazz Pharmaceuticals plc...
1:44 PM, Aug 03, 2018  |  BioCentury | Finance

Lin’s new chapters

Taiwanese biotech Lin Bioscience Inc. and its wholly owned San Diego subsidiary Lin Bioscience Co. Ltd. are planning sequential listings in Taiwan and the U.S. to fund clinical programs targeting different markets. Lin has two preclinical...
1:43 PM, Aug 03, 2018  |  BioCentury | Finance

Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies. Along with...
5:24 PM, Aug 02, 2018  |  BioCentury | Finance

Appetite for Omniome

An experienced team and a growing DNA sequencing market in China enabled San Diego’s Omniome Inc. to raise a $60 million series B round led by Chinese investors. Decheng Capital and Hillhouse Capital Group co-led...
2:28 PM, Aug 01, 2018  |  BioCentury | Finance

Safety goes (Re)Viral

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners. The round...
3:19 PM, Jul 27, 2018  |  BioCentury | Regulation

Getting into action

In its Biosimilars Action Plan, FDA promises to address most of the hot button regulatory issues that have slowed development of biosimilars and interchangeable biologics for the U.S. market. FDA can do little, however, to...
2:26 PM, Jul 27, 2018  |  BioCentury | Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...